Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern

5 Mar 2025

Abstract excerpt

The ongoing emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that reduce the effectiveness of antibody therapeutics necessitates development of next-generation antibody modalities that are resilient to viral evolution. Here, we characterized amino-terminal domain (NTD)- and receptor binding domain (RBD)-specific monoclonal antibodies previously isolated from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to Monoclonal and Polyclonal Antibodies Research
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40043139
DOI: 10.1126/scitranslmed.adq5720

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concernPMID 40043139Read ↗

A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variantsSemantic proximity Read ↗

Broad-Spectrum Heavily Mutated Monoclonal Antibody Isolated from COVID-19 Convalescent Vaccinee with Capacity to Neutralize SARS-CoV2 Variants Ranging from B.1 to BQ.1.1Semantic proximity Read ↗

Potent neutralization by a receptor binding domain monoclonal antibody with broad specificity for SARS-CoV-2 JN.1 and other variantsSemantic proximity Read ↗

Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variantsSemantic proximity Read ↗

Potent neutralization by a RBD antibody with broad specificity for SARS-CoV-2 JN.1 and other variantsSemantic proximity Read ↗

Structural and mutational analyses define distinct molecular routes to broad SARS-CoV-2 receptor-binding domain recognitionSemantic proximity Read ↗

A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and OmicronSemantic proximity Read ↗

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variantsSemantic proximity Read ↗

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of ConcernSemantic proximity Read ↗

Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients.Semantic proximity Read ↗

Dual Epitope Engagement Enables Broad-Spectrum Neutralization of SARS-CoV-2 Variants by Bispecific Antibody 9A6-6C3Semantic proximity Read ↗

A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBDSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.